We tested the hypothesis that liver protein kinase C (PKC) is increased in non-insulin-dependent diabetes mellitus (NIDDM). To this end we examined the distribution of PKC isozymes in liver biopsies from obese individuals with and without NIDDM and in lean controls. PKC isozymes a, 13, e and g were detected by immunoblotting in both the cytosol and membrane fractions. Isozymes y and 6 were not detected. There was a significant increase in immunodetectable PKC-a (twofold), -E (threefold), and -C (twofold) in the membrane fraction isolated from obese subjects with NIDDM compared with the lean controls. In obese subjects without NIDDM, the amount of membrane PKC isozymes was not different from the other two groups. We next sought an animal model where this observation could be studied further. The Zucker diabetic fatty rat offered such a model system. Immunodetectable membrane PKC-ci, -13, -e, and -t were significantly increased when compared with both the lean and obese controls. The increase in immunodetectable PKC protein correlated with a 40% elevation in the activity of PKC at the membrane. Normalization of circulating glucose in the rat model by either insulin or phlorizin treatment did not result in a reduction in membrane PKC isozyme protein or kinase activity. Further, phlorizin treatment did not improve insulin receptor autophosphorylation nor did the treatment lower liver diacylglycerol. We conclude that liver PKC is increased in NIDDM, a change that is not secondary to hyperglycemia. It is possible that PKCmediated phosphorylation of some component in the insulin signaling cascade contributes to the insulin resistance observed in NIDDM. (J. Clin. Invest. 1995Invest. .95:2938Invest. -2944
Introduction
Insulin resistance is a hallmark of non-insulin-dependent diabetes mellitus (NIDDM)1 (1) (2) (3) (4) (5) (6) (7) (8) (9) . Protein kinase C (PKC) has been implicated in the development of insulin resistance in a variety of isolated cell and tissue systems (10) (11) (12) (13) (14) . Of particular interest to the present study, phorbol ester-induced activation of PKC in rat hepatocytes results in a reduction in insulinstimulated glycogen (15, 16) and lipid synthesis (15) . More recently, insulin resistance was induced by transfection with PKC specific cDNA and subsequent activation of the expressed kinase in cultured cells (17) . Although PKC-mediated phosphorylation and inactivation of the insulin receptor tyrosine kinase has been demonstrated in vitro (18, 19) , other studies have suggested that receptor phosphorylation is not a requirement for activated PKC to cause insulin resistance (20, 21) . It is therefore plausable to expect that PKC would be increased in tissue from NIDDM patients and that this increase could contribute to the observed insulin resistance. For this reason we have compared the distribution of PKC isozymes in liver from obese patients with NIDDM with that in obese or lean patients without NIDDM. The isozymes were also examined in Zucker diabetic fatty (ZDF) rat liver, a genetically derived animal model of type II diabetes (22) . In addition, the effect of plasma glucose concentration on PKC activity, isozyme distribution, and diacylglycerol (DAG) content of the ZDF rat liver was investigated. The results suggest that PKC may be involved in insulin resistance; however, hyperglycemia does not appear to affect PKC metabolism in the liver.
Methods
Materials. Anti-PKC polyclonal antibodies and nitrocellulose-1 were obtained from GIBCO BRL (Grand Island, NY). Monoclonal antibodies for PKC-a, -p3, and -e were purchased from Transduction Laboratories (Lexington, KY). Horseradish peroxidase-linked anti-rabbit or antimouse antibody, enhanced chemiluminescence kit and DAG assay were Human subjects. 15 individuals were studied: 5 obese with NIDDM, 5 obese without diabetes, and 5 lean subjects. All individuals signed informed consent. The characteristics of the study groups are presented in Table I . These subjects do not differ significantly from those studied previously by this laboratory (4) . After opening the abdomen, a 1-2-g biopsy was obtained from the left lobe of the liver and immediately frozen in liquid nitrogen. The tissue was stored at -800C until used.
Animals. ZDF rats (ZDF/Gmi'-fa/fa) and their lean littermates (ZDF/GmiTm) were purchased from Genetic Models Inc. (Indianapolis, As a control, three additional obese/diabetic rats were given an equal volume of saline. Blood glucose was monitored daily before the insulin injection using an Accu-Chek Easy glucose meter (model no. 788).
Phlorizin treatment. Six obese/diabetic rats were given phlorizin (0.4 g/kg body wt dissolved in propylene glycol) by subcutaneous injection every 8 h over a 10-d period. As a control six additional obese/ diabetic rats received vehicle alone. Blood glucose was monitored daily in the morning (Accu-Chek Easy, model no. 788).
Insulin receptor autophosphorylation. Wheat germ agglutinin-purified insulin receptors were prepared as described previously (4, 13).
Solubilized receptors (5 pg) were diluted to 100 Al in 50 mM Hepes (pH 7.4), 5 mM MnCl2. Receptors were preincubated in the presence or absence of I0-7 M or 10-9 M insulin for 15 min at room temperature. Phosphorylation was initiated by the addition of [ y-32P]ATP (25 ,uM final concentration) and allowed to proceed for 10 min. The reaction was stopped by the addition of 2x Laemmli buffer followed by boiling for 5 min. Insulin receptor /3-subunit was separated from the other protein by SDS-PAGE, and the amount of autophosphorylation was quantitated by phosphoimager analysis (Molecular Dynamics, Sunnyvale, CA). The insulin-binding capacity of each preparation was determined as previously described (4) and was used to normalize the autophosphorylation data.
Diacylglycerol assay. sn-1,2-diacylglycerol was extracted from the liver by the method of Bligh and Dyer (23) . 0.25 g of frozen tissue was homogenized in 3 ml of chloroform:methanol (1:2, vol/vol), followed by the addition of 1 ml of 1 M NaCl and then 1 ml of chloroform with vortexing. 1 ml of 1 M NaCl was then added to break the phases. The samples were centrifuged at 3,000 g for 2 min, and the lower chloroform phase taken for analysis of DAG by the method of Preiss et al. (24) Distribution ofPKC isozymes in rat liver. Cytosol and membrane fractions were prepared from lean, obese, and obese/ diabetic rat liver in a manner similar to that for the human liver as described above. The physiological characteristics of the three animal groups are outlined in Table II .
As observed in human liver there was significantly more PKC-a, -e, and -4 present in the membrane fraction isolated from the obese/diabetic rats than in the membrane fraction isolated from the lean rats ( Fig. 2 and Table III ). In contrast to our findings in human liver, the amount of these PKC isozymes in the obese rat liver membrane fractions was identical to that in the lean rats and was significantly different from that in the obese/diabetic animals. These findings were confirmed using monoclonal antibodies for PKC-a and -e (data not shown). In addition, using a monoclonal antibody for detection, there was significantly more PKC-,6 in the membrane fraction isolated from the obese/diabetic group compared with the lean. There was no difference in the amount of cytosolic PKC-a, -,6, -e, or -4 among the three groups of rats (Table III) .
PKC activity in rat liver. Further evidence for the differen- Figure 2 . Membrane PKC-a is increased in liver of obese/diabetic rats. Data were generated as described in Fig. 1 . Representative band density is illustrated above the graph. Note that in contrast to obese humans ( Fig. 1 tial localization of PKC in obese/diabetic liver is provided by activity measurements in both the cytosol and membrane fractions. Activity was defined as the phosphorylation of histone protein in the presence of phosphatidylserine, diolein, and calcium minus that in the presence of EGTA. As shown in Fig. 3 , there was a statistically significant 40% elevation in the activity of membrane-associated PKC in the obese/diabetic group. There was no difference in the activity of kinase in the cytosolic fractions (lean: 269±55; obese: 259±60; obese/diabetic: 242±46 pmol/mg per min). Insulin treatment of obese/diabetic rats. To evaluate the possibility that the increase in membrane PKC was due to the hyperglycemia in diabetes, three obese/diabetic rats were given supplemental insulin to lower blood sugar. As shown in Fig. 4 A, insulin was effective in keeping blood glucose near normal for the duration of the study. The insulin-treated animals gained more weight over the period than the controls (96±6 vs. 26+10 g; P < 0.05).
As illustrated in Fig. 4 B, insulin treatment had no effect on the activity of membrane-associated PKC when compared with the activity in the untreated obese/diabetic controls. Immunoblotting failed to detect any difference.in the amount of membrane-associated PKC-a (0.18±0.03), -E (0.02±0.01), -70 kD 4 Insulin treatment resulted in a 64% increase in total liver DAG content. Animals receiving insulin had a liver DAG content of 935±95 pmol/mg tissue compared with 570±57 pmol/ mg tissue in the obese/diabetics receiving vehicle only (P < 0.05; one-way ANOVA).
Phlorizin treatment of obese/diabetic rats. To address the potential effect of insulin and to evaluate further the role of circulating glucose on membrane PKC, six obese/diabetic rats were administered phlorizin to reduce plasma glucose. As illustrated in Fig. 5 A, phlorizin reduced circulating plasma glucose to near normal levels over a 10-d period. Insulin levels measured at killing were reduced 37% (P < 0.05; one-way ANOVA) in the treated rats compared with those receiving vehicle.
Normalization of plasma glucose with phorizin had no effect on membrane-associated PKC activity (Fig. 5 B) . In addition, immunoblotting failed to detect any difference in the amount of membrane-associated PKC-a (0.38±0. In addition to the lack of a reduction in membrane PKC, phlorizin treatment did not improve the activity of the insulin receptor tyrosine kinase. As illustrated in Fig. 6 , insulin-stimulated autophosphorylation was reduced 45% in the diabetic rat liver compared with the lean rats, a situation not improved by phlorizin-induced euglycemia. DAG content of rat liver. The sn-1,2-diacylglycerol content of the obese/diabetic rat liver was determined as a possible contributing factor to the persistent PKC activation in these animals. Obese/diabetic rat liver contained three times as much DAG as that detected in the lean animal liver (Fig. 7) . Phlorizin treatment did not result in a significant reduction in the amount of DAG. It should be noted that in the obese nondiabetic rat liver DAG was also elevated to a level not statistically different from that observed in the liver of the obese/diabetic animals. . Insulin receptor tyrosine kinase activity after phlorizin treatment. Insulin receptors were prepared and autophosphorylation was determined as described in Methods. Phlorizin treatment did not improve receptor tyrosine kinase activity. Values represent the mean+SEM for four lean, three obese, five obese/diabetic, and four phlorizin-treated animals. *P < 0.05; compared with the other three groups. Figure 7 . Diacylglycerol content of rat liver. sn-1,2-DAG was measured using the diacylglycerol kinase method. Values represent the mean±SEM for four lean, five obese, five obese/diabetic, and four phlorizin-treated animals. *P < 0.005; compared with the other three groups.
Discussion
Using isozyme-specific antibodies, we identified PKC-a, -/, -e, and -4 in both human and rat liver. We were unable to detect the -y or -6 isoforms. To our knowledge this is the first characterization of the PKC isozymes in human liver. Further, our findings in the rat liver are in general agreement with those of other investigators (25, 26) . Although the antibody for PKC-4 detected two bands (27, 28) , the recent study of Ha and Exton (29) suggests that the 80-kD band may result from crossreactivity with PKC-a.
Having characterized the isozymes present, we next tested the hypothesis that liver PKC is increased in NIDDM. To this end we studied in humans and rats three metabolic states: obese with NIDDM, obese without NIDDM, and lean without NIDDM. PKC-a, -e, and -I were elevated in the liver membranes of the obese/diabetics when compared with the lean controls in both humans and rats. PKC-f3 was also elevated in the obese/diabetic rats; however, we were unable to quantitate this isozyme in humans because of limited supply of tissue. Immunodetectable PKC was different in the obese state between humans and rats. In human obesity the amount of PKC isozyme was not different either from the lean or obese/diabetics. Although this may be due in part to the small group of patients studied, it is of interest that obese human liver is more insulin resistant than that from lean individuals but less than that from diabetic subjects (4) . In contrast to the human liver, the amount of PKC isozyme in the insulin-resistant obese rats (30, 31 ) was similar to that in the lean and significantly less than that in the obese/diabetic animals. These differences between the human and rat model could represent degrees of severity of insulin resistance. Alternatively, the insulin resistance of the obese Zucker rat liver could be due to a mechanism different from that of humans.
Because the alterations in liver PKC metabolism in the rat model of NIDDM were similar to those in the patients with NIDDM, elevated plasma glucose was examined as a possible cause of the increase in membrane PKC. Glucose-induced increases in DAG and membrane PKC have been demonstrated previously in different tissues (32) (33) (34) , and inhibitors of PKC have been shown to prevent glucose-induced insulin resistance in rat fat cells (14) . Cumulatively, these observations support a hypothesis that hyperglycemia leads to PKC activation and possibly insulin resistance. 2942 Considine et al. To circumvent the uncertainties associated with insulin treatment, we used phlorizin to lower plasma glucose. This drug acts in the renal tubule to prevent glucose transport, resulting in enhanced glucose excretion (37, 38) . Phlorizin treatment resulted in a normalized plasma glucose concentration that was maintained for 10 d. Despite this rather lengthy euglycemic period, membrane PKC was not different from that in the obese/ diabetic controls administered vehicle. The sustained increase in membrane PKC may have been due to the elevation in liver DAG, which was unaltered by lowering blood glucose. However, it should be noted that the level of DAG in the obese rat liver was similar to that in the obese/diabetic animals, yet there was no significant elevation in membrane PKC. This observation suggests that the bulk of the DAG measured in liver is probably not associated with signaling but rather triglyceride synthesis stimulated by elevated insulin levels. In any respect, the elevation in membrane PKC in NIDDM liver does not appear to be due to hyperglycemia as would be suggested by the studies described above.
One other recent study examined the distribution of PKC isozymes in diabetic rat liver (26) . Streptozotocin-induced diabetes increased the amount of PKC-a and -pHII in both the cytosol and membrane fraction and PKC-e in the membrane fraction only. Insulin treatment of the diabetic animals reduced cytosolic PKC-a and -,pH and decreased membrane PKC-e to below that of normal control animals. One major difference between the study of Tang et al. (26) and the present one is that the diabetic state is chemically induced and characterized by elevated plasma glucose with little or no circulating insulin. In this case changes in PKC may be due to the hyperglycemia, and therefore would be reversible with normalization of plasma glucose with insulin.
If the elevation in membrane PKC in insulin-resistant liver is not due to hyperglycemia, what are the other possibilities? Differences in the lipid composition of, or the microsomal contribution from other organelles to, the crude membrane preparation cannot be ruled out in this study. An alternative membranerelated possibility may reside in the phosphoinositide signal cascade. We have documented previously an increase in liver phosphatidylinositol 4,5-bisphosphate specific phospholipase C activity in NIDDM (39) . This would result in increased IP3 and thus Ca2", which has been shown to induce insulin resistance (40) . This would also increase DAG and thus PKC activation.
The second possibility may involve insulin and insulin resistance. Kanety et al. (41 ) have documented recently that hyperinsulinemia in the sand rat model of NIDDM led to impairment in insulin receptor function. If PKC is activated by insulin (35, 36, 42, 43 ) , it could also function as the feedback switch responsible for turning off the insulin receptor.
The final possibility is that the increase in PKC is primary to NIDDM. This is highly unlikely because at least one alteration we believe to be due to the increase in PKC, namely the decrease in insulin receptor tyrosine kinase activity, is reversible after weight loss and improvement in insulin action (44) . The fact that PKC did not decrease after insulin-or phlorizin-induced euglycemia in still insulin-resistant animals is not inconsistent with the notion that PKC would normalize with weight loss, exercise, or pharmacologic therapy aimed to improve insulin action.
What is the mechanism through which PKC would contribute to or cause insulin resistance? Most work has focused on PKC-mediated serine/threonine phosphorylation of the insulin receptor resulting in inactivation of the tyrosine kinase and the development of insulin resistance (10) (11) (12) (13) (14) (15) (17) (18) (19) , although this finding has not been universal (16, 45) . Interestingly, Anderson and Olefsky (20) demonstrated a PMA-mediated inhibition of the insulin receptor tyrosine kinase and an increase in insulin resistance in cells expressing a truncated receptor lacking the major PKC phosphorylation site. Along similar lines, the work of Zachayus et al. (21) suggests that although PMAactivated PKC results in insulin resistance in permeabilized fetal hepatocytes, PKC is not directly responsible for the increase in serine phosphorylation of the insulin receptor. These studies suggest that the role of PKC in insulin resistance may not be the result of a direct interaction of the kinase with the receptor. Other possibilities could include PKC-mediated activation of another kinase or an insulin receptor specific phosphatase. Further work is necessary to determine the exact mechanism through which PKC contributes to insulin resistance.
In summary, we have detected a significant elevation in the PKC isozymes a, E, and 4 in liver tissue from both humans and rats with NIDDM. PKC-/3 was also increased in the diabetic rat liver. The increase in isozyme protein is accompanied by an increase in membrane-associated PKC activity. The increase in membrane PKC does not appear to be due to hyperglycemia but to some other factor in the individual with insulin resistance. These observations support the hypothesis that aberrant PKC activity may result in insulin resistance.
